Robuta

https://global.pharmcube.com/news/detail/f2590817763848dd808d006a9ba62820?type=dailyNews
The PharmCube News & Reports module provides professional pharmaceutical knowledge services. Powered by in-depth data analysis, it highlights industry trends...
sanofireportsresultsusdkey
https://stockhouse.com/opinion/independent-reports/2019/09/24/regeneron-reports-positive-phase-3-dupixent-data-gains-eu-approval
Regeneron Pharmaceuticals published positive results from two U.S. Phase 3 trials evaluating the safety and efficacy of Dupixent (dupilumab) in adults with...
regeneronreportspositivephasedupixent
https://www.pharmaceutical-technology.com/news/dupixent-gains-chronic-spontaneous-urticaria-indication-in-europe/
Nov 26, 2025 - The approval marks the first for a targeted treatment in chronic spontaneous urticaria in Europe in over a decad
chronic spontaneous urticariain europepharmaceutical technologydupixentgains